**Author details**

Goran Imamović1,2\*, Bernard Canaud3,4, Nusret Mehmedović<sup>5</sup> and Cäcilia Scholz6

\*Address all correspondence to: goran.imamovic@fmc-ag.com

1 Fresenius Medical Care, Deutschland GmbH, Germany

2 School of Medicine, University of Tuzla, Tuzla, Bosnia and Herzegovina

3 Centre of Excellence Medical, FMC-EMEA, Bad Homburg, Germany

4 School of Medicine, Montpellier University, Montpellier, France

5 Fresenius Medical Care, Bosnia and Herzegovina GmbH, Bosnia and Herzegovina

6 Fresenius Medical Care, Deutschland GmbH, Germany

#### **References**


[13] Canaud, B., et al., Evaluation of high-flux hemodiafiltration efficiency using an on-line urea monitor. Am J Kidney Dis, 1998. 31(1): p. 74–80.

2 School of Medicine, University of Tuzla, Tuzla, Bosnia and Herzegovina

5 Fresenius Medical Care, Bosnia and Herzegovina GmbH, Bosnia and Herzegovina

[1] Yavuz, A., et al., Uremic toxins: a new focus on an old subject. Semin Dial, 2005. 18(3):

[2] Lowrie, E.G., et al., Effect of the hemodialysis prescription of patient morbidity: report from the National Cooperative Dialysis Study. N Engl J Med, 1981. 305(20): p. 1176–81.

[3] The United Renal Data System, Overall hospitalization and mortality. Am J Kidney

[4] Collins, A.J., et al., Excerpts from the US Renal Data System 2009 Annual Data Report.

[5] Lowrie, E.G., N.M. Laird, and R.R. Henry, Protocol for the National Cooperative

[6] Eknoyan, G., et al., Effect of dialysis dose and membrane flux in maintenance hemo‐

[7] Winchester, J.F., J.A. Salsberg, and N.W. Levin, Beta-2 microglobulin in ESRD: an in-

[8] K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney

[9] Gejyo, F., et al., Beta 2-microglobulin: a new form of amyloid protein associated with

[11] Miyata, T., et al., Beta-2 microglobulin in renal disease. J Am Soc Nephrol, 1998. 9(9):

[12] Locatelli, F., et al., Effect of membrane permeability on survival of hemodialysis

[10] Koch, K.M., Dialysis-related amyloidosis. Kidney Int, 1992. 41(5): p. 1416–29.

3 Centre of Excellence Medical, FMC-EMEA, Bad Homburg, Germany

4 School of Medicine, Montpellier University, Montpellier, France

Am J Kidney Dis, 2010. 55(1 Suppl 1): p. S1–420, a6–7.

Dialysis Study. Kidney Int Suppl, 1983(13): p. S11-8.

depth review. Adv Ren Replace Ther, 2003. 10(4): p. 279–309.

disease . Am J Kidney Dis, 2003. 42(4 Suppl 3): p. S1-201.

chronic hemodialysis. Kidney Int, 1986. 30(3): p. 385–390.

patients. J Am Soc Nephrol, 2009. 20(3): p. 645–54.

dialysis. N Engl J Med, 2002. 347(25): p. 2010–9.

6 Fresenius Medical Care, Deutschland GmbH, Germany

**References**

20 Advances in Hemodiafiltration

p. 203-11.

p. 1723–35.

Dis, 2010. 55(Suppl 1): p. S1.


[42] Penne, E.L., et al., Effect of increased convective clearance by on-line hemodiafiltration on all cause and cardiovascular mortality in chronic hemodialysis patients - the Dutch CONvective TRAnsport STudy (CONTRAST): rationale and design of a randomised controlled trial [ISRCTN38365125]. Curr Control Trials Cardiovasc Med, 2005. 6(1): p. 8.

[28] Lornoy, W., et al., Remarkable removal of beta-2-microglobulin by on-line hemodia‐

[29] Penne, E.L., et al., Short-term effects of online hemodiafiltration on phosphate control: a result from the randomized controlled Convective Transport Study (CONTRAST).

[30] Beerenhout, C.H., et al., Pre-dilution on-line haemofiltration vs low-flux haemodialy‐ sis: a randomized prospective study. Nephrol Dial Transplant, 2005. 20(6): p. 1155–63.

[31] Gatti, E. and C. Ronco, Seeking an optimal renal replacement therapy for the chronic kidney disease epidemic: the case for on-line hemodiafiltration. Contrib Nephrol, 2011.

[32] Canaud B., K. Pascal, R. Spickermann, and E. Gatti, Online Hemodiafiltration by Fresenius Medical Care. In: Nubé M.J. , Grooteman M.P.C., Blankestijn P., editors. Hemodiafiltration: Theory, Technology and Clinical Practice. 1st ed. Springer Interna‐

[33] Potier, J., G. Queffeulou, J. Bouet, Autosub Plus. A sophisticated innovative tool for a simplified OL-HDF practice. Nephrol Dial Transplant Rev (Orlando), 2013. 28 (suppl

[34] Donauer, J., et al., Reduction of hypotensive side effects during online-haemodiafiltra‐ tion and low temperature haemodialysis. Nephrol Dial Transplant, 2003. 18(8): p. 1616–

[35] Locatelli, F., et al., Hemofiltration and hemodiafiltration reduce intradialytic hypoten‐

[36] Cheung, A.K., et al., Serum beta-2 microglobulin levels predict mortality in dialysis patients: results of the HEMO study. J Am Soc Nephrol, 2006. 17(2): p. 546–55.

[37] Pedrini, L.A., et al., Long-term effects of high-efficiency on-line haemodiafiltration on uraemic toxicity. A multicentre prospective randomized study. Nephrol Dial Trans‐

[38] Di Filippo, S., et al., Sodium removal during pre-dilution haemofiltration. Nephrol Dial

[40] Zehnder, C., et al., Influence of long-term amelioration of anemia and blood pressure control on left ventricular hypertrophy in hemodialyzed patients. Nephron, 1992. 61(1):

[41] Ok, E., et al., Mortality and cardiovascular events in online haemodiafiltration (OL-HDF) compared with high-flux dialysis: results from the Turkish OL-HDF Study.

[39] Kawanishi, H., A.C. Yamashita, Haemodiafiltration: A New Era. Karger, 2011.

sion in ESRD. J Am Soc Nephrol, 2010. 21(10): p. 1798–807.

Transplant, 2003. 18 Suppl 7: p. vii31–6; discussion vii57–8.

Nephrol Dial Transplant, 2013. 28(1): p. 192–202.

filtration. Am J Nephrol, 1998. 18(2): p. 105–8.

tional Publishing Switzerland, 2016. p. 95–102.

Am J Kidney Dis, 2010. 55(1): p. 77–87.

175: p. 170–85.

22 Advances in Hemodiafiltration

1): p. i207.

plant, 2011. 26(8): p. 2617–24.

22.

p. 21–5.

